logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2019 – Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

Promising results from the ad interim analysis of the ASCEND Study investigating acalabrutinib monotherapy were presented for the first time at EHA congress